ChiCTR2500115116 版本V1.0 版本创建时间2025/12/23 08:40:51 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500115116 

最近更新日期:

Date of Last Refreshed on:

2025-12-23 08:40:34 

注册时间:

Date of Registration:

2025-12-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

全关节镜下微创植骨术联合PRP凝胶注射治疗重度距骨软骨损伤的临床研究

Public title:

A clinical study of all-arthroscopic minimally invasive bone grafting combined with prp gel injection for the treatment of advanced osteochondral lesions of the talus

注册题目简写:

English Acronym:

研究课题的正式科学名称:

全关节镜下微创植骨术联合PRP凝胶注射治疗重度距骨软骨损伤的临床研究

Scientific title:

A clinical study of all-arthroscopic minimally invasive bone grafting combined with prp gel injection for the treatment of advanced osteochondral lesions of the talus

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

韩皓 

研究负责人:

曹广超 

Applicant:

Hao Han 

Study leader:

Guangchao Cao 

申请注册联系人电话:

Applicant telephone:

+86 185 5293 8939

研究负责人电话:

Study leader's
telephone:

+86 138 1531 8074

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hanh4973@163.com

研究负责人电子邮件:

Study leader's E-mail:

18553938939@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省徐州市经济技术开发区杨山路11号

研究负责人通讯地址:

江苏省徐州市经济技术开发区杨山路11号

Applicant address:

No 11, Yangshan Road, Xuzhou Economic Development Zone, Xuzhou City, Jiangsu Province, China

Study leader's address:

No 11, Yangshan Road, Xuzhou Economic Development Zone, Xuzhou City, Jiangsu Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

徐州仁慈医院

Applicant's institution:

Xuzhou Renci Hospital

研究负责人所在单位:

徐州仁慈医院

Affiliation of the Leader:

Xuzhou Renci Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

XZRCLL-KT-202511001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

徐州仁慈医院伦理审查委员会

Name of the ethic committee:

Ethics Committee of Xuzhou Renci Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-07-30 00:00:00

伦理委员会联系人:

张家萌

Contact Name of the ethic committee:

Jiameng Zhang

伦理委员会联系地址:

江苏省徐州市经济技术开发区杨山路11号

Contact Address of the ethic committee:

No 11, Yangshan Road, Xuzhou Economic Development Zone, Xuzhou City, Jiangsu Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 516 8732 6080

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

徐州仁慈医院

Primary sponsor:

Xuzhou Renci Hospital

研究实施负责(组长)单位地址:

江苏省徐州市经济技术开发区杨山路11号

Primary sponsor's address:

No 11, Yangshan Road, Xuzhou Economic Development Zone, Xuzhou City, Jiangsu Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

徐州市

Country:

China

Province:

Jiangsu

City:

Xuzhou

单位(医院):

徐州仁慈医院

具体地址:

江苏省徐州市经济技术开发区杨山路11号

Institution
hospital:

Xuzhou Renci Hospital

Address:

No 11, Yangshan Road, Xuzhou Economic Development Zone, Xuzhou City, Jiangsu Province, China

经费或物资来源:

徐州市卫生健康委员会医学科技创新立项项目

Source(s) of funding:

Xuzhou Medical Science and Technology Innovation Project of Xuzhou health care commission

研究疾病:

距骨软骨损伤  

Target disease:

osteochondral lesions of the talus

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究将围绕关节镜下微创植骨术联合关节腔注射富血小板血浆凝胶(platelet?rich plasma,PRP)治疗距骨骨软骨损伤(osteochondral lesions of the talus,OLT)相关技术开展研究,探讨OSE-MTLIF临床疗效,安全性及技术推广等。其研究的具体目的及意义为: (1) 临床疗效:目的:全面评估关节镜下微创植骨联合PRP注射治疗OLT的中远期临床疗效、影像学修复质量及手术安全性。 (2)技术推广:目的:基于临床疗效研究,构建关节镜微创植骨联合PRP治疗OLT的技术培训体系,推动该技术的规范化、普及化应用。  

Objectives of Study:

This study will focus on the techniques associated with arthroscopic minimally invasive bone grafting combined with intra-articular injection of platelet-rich plasma (PRP) gel for the treatment of osteochondral lesions of the talus (OLT). It aims to investigate the clinical efficacy, safety, and potential for widespread adoption of this technique. The specific objectives and significance of the research are as follows: (1) ?Clinical Efficacy? ?Objective:?? To comprehensively evaluate the medium- to long-term clinical outcomes, quality of radiographic repair, and surgical safety of arthroscopic minimally invasive bone grafting combined with PRP injection in the treatment of OLT. (2) ?Technical Promotion? ?Objective:?? Based on clinical efficacy research, to establish a structured training protocol for arthroscopic minimally invasive bone grafting combined with PRP in treating OLT, thereby promoting the standardized and widespread application of this technique.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1) 年龄18-60岁; (2) 踝关节慢性疼痛,经踝关节影像学检查确定为重度距骨骨软骨损伤; (3) 采用休息/外用药/口服非甾体类抗炎药等保守治疗3个月以上效果不佳者; (4) 患者自愿参加临床试验,签署知情同意书,能够配合临床随访并获得完整资料;

Inclusion criteria

(1) Aged between 18 and 60 years; (2) Chronic ankle pain with imaging-confirmed severe osteochondral lesions of the talus; (3) History of unsuccessful conservative treatment (including rest, topical agents, or oral nonsteroidal anti-inflammatory drugs) for at least 3 months; (4) Voluntarily participation in the clinical trial with signed informed consent, and ability to comply with clinical follow-up and provide complete data.

排除标准:

(1) 踝关节力线不正(内翻或外翻>5度); (2) 慢性特异性滑膜炎、关节纤维化、关节强直,活动明显受限者; (3) 中、重度骨性关节炎者(Takakura分期为Ⅲ期或Ⅳ期); (4) 重要脏器功能障碍或严重内科疾病,不能耐受手术者; (5)精神或神经性疾病患者; (6)妊娠或计划妊娠妇女及哺乳期女性。

Exclusion criteria:

(1) Malalignment of the ankle joint (varus or valgus greater than 5 degrees); (2) Chronic specific synovitis, joint fibrosis, or joint ankylosis resulting in significantly limited range of motion; (3) Moderate to severe osteoarthritis (Takakura stage III or IV); (4) Dysfunction of major organs or severe underlying medical diseases rendering the patient unfit for surgery; (5) Patients with psychiatric or neurological disorders; (6) Pregnant or lactating women, or women planning a pregnancy.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00

干预措施:

Interventions:

组别:

关节镜微创植骨+PRP注射组

样本量:

50

Group:

Arthroscopic minimally invasive bone grafting combined with PRP injection group

Sample size:

干预措施:

关节镜下微骨折术联合松质骨移植术联合PRP注射术

干预措施代码:

Intervention:

Arthroscopic microfracture combined with cancellous bone grafting and PRP injection

Intervention code:

组别:

关节镜微创植骨组

样本量:

50

Group:

Arthroscopic minimally invasive bone grafting group

Sample size:

干预措施:

关节镜下微骨折术联合松质骨移植术

干预措施代码:

Intervention:

Arthroscopic microfracture combined with cancellous bone grafting

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

徐州市 

Country:

China

Province:

Jiangsu

City:

Xuzhou

单位(医院):

徐州仁慈医院 

单位级别:

三甲 

Institution
hospital:

Xuzhou Rcenci Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

视觉模拟评分法

指标类型:

主要指标

Outcome:

visual anlogue scale, VAS

Type:

Primary indicator

测量时间点:

术前、术后1、3、6月、1年

测量方法:

Measure time point of outcome:

Preoperative and postoperative (1, 3, 6, and 12 months)

Measure method:

指标中文名:

软骨修复组织磁共振(MOCART)评分系统

指标类型:

主要指标

Outcome:

magneicresonance obseraion of cartlage repair tissue

Type:

Primary indicator

测量时间点:

术前、术后1年

测量方法:

Measure time point of outcome:

Preoperative and postoperative 12 months

Measure method:

指标中文名:

美国足踝外科协会评踝-后足功能评分

指标类型:

主要指标

Outcome:

American Orthopaedic Foot and Ankle Society, AOFAS

Type:

Primary indicator

测量时间点:

术前、术后1、3、6月、1年

测量方法:

Measure time point of outcome:

Preoperative and postoperative (1, 3, 6, and 12 months)

Measure method:

指标中文名:

足踝关节预后评分

指标类型:

主要指标

Outcome:

Foot and Ankle Outcome Score, FAOS

Type:

Primary indicator

测量时间点:

术前、术后1、3、6月、1年

测量方法:

Measure time point of outcome:

Preoperative and postoperative (1, 3, 6, and 12 months)

Measure method:

指标中文名:

踝关节活动评分

指标类型:

主要指标

Outcome:

Ankle Activity Score, AAS

Type:

Primary indicator

测量时间点:

术前、术后1、3、6月、1年

测量方法:

Measure time point of outcome:

Preoperative and postoperative (1, 3, 6, and 12 months)

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表法

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

收集和处理数据的人员不知道手术方式

Blinding:

The personnel responsible for data collection and processing were blinded to the surgical procedures.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

None

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-12-23 08:40:34